Tue, Jul 13, 2021

Life Sciences Webcast Series

Kroll recently hosted a webcast series that brought together our leading experts and industry leaders to share insights on trends, valuation, technology, intellectual property (IP), risk and regulation in the life sciences industry. Please see below for more details on each session and a link to the event replays.

Key Insights and Trends

Life Sciences - Key Insights and Trends

As big pharma and biotech conglomerates continue to seek growth following the COVID-19 pandemic, our experts provide insights on what will shape the future of the life sciences industry and dissect the key drivers of M&A activity.

Key Insights

  • Deal trends and investment opportunities 
  • Digitalization and remote engagement in healthcare
  • The importance of environmental, social, and corporate governance (ESG)


  • Andreas Chrysostomou, Managing Director, Duff & Phelps
  • Brooks Dexter, Managing Director, Duff & Phelps
  • Andrew Probert, Managing Director, Duff & Phelps
  • James D’Arecca, Chief Financial Officer, TherapeuticsMD

Biotechnology Purchase Accounting Valuation

Life Sciences - Biotechnology Purchase Accounting Valuation

Purchase accounting valuation in the biotechnology industry can be particularly challenging. Understanding the intricacies of biotechnology valuation and having command best practices is key to successfully navigating the valuation process for all stakeholders. Duff & Phelps’ Life Sciences valuation advisory team walk you through a purchase price allocation for a hypothetical biotechnology company based on real world experience. 

Key Insights

  • Key considerations and intricacies regarding unit of account decisions in product/product candidate valuation.
  • Unique inventory valuation considerations in biotechnology acquisitions
  • Valuation of biotechnology collaborations/licensing arrangements
  • Contingent liability and contingent consideration valuation
  • Navigating the audit process and documentation


  • Andreas Chrysostomou, Managing Director, Duff & Phelps
  • Jonathan Goldblatt, Managing Director, Duff & Phelps 
  • Frank Deluca, Director, Duff & Phelps
  • David Nadel, Director, Duff & Phelps

The Impact of Technology

Life Sciences - The Impact of Technology

Technology continues to impact the relationship between businesses and their stakeholders, with data exchange, digital service provision and innovation all driving discussion. Our panel of experts address data-driven approaches to patient care, the impact of technology on regulation, and IP, data privacy and cyber security issues in the healthcare and life sciences industry.

Key Insights

  • Using technology to analyze data and provide better patient care
  • The impact of regulation on the modernization of compliance programs 
  • Safeguarding IP with privacy, cyber and IT procedures
  • Balancing data privacy, cyber and the efficient exchange of patient data
  • Protecting assets against cyber-attacks and unforced errors


  • Alpa Kamdar, Managing Director, Duff & Phelps
  • Stacy Scott, Managing Director, Kroll 

Intellectual Property – Management, Protection and Enforcement

Life Sciences - Intellectual Property

Our panel of leading attorneys discuss current issues facing the life sciences industry with respect to the management, protection and enforcement of IP rights in the UK, Europe and the U.S.

Key Insights

  • Cross-border challenges
  • The UK and Europe post Brexit
  • The International Trade Commission
  • The impact of biosimilars on the IP landscape


  • Pauline Booth, Managing Director, Duff & Phelps
  • Barbara Fiacco, Partner, Foley Hoag
  • Dr. Penny Gilbert, Partner, Powell Gilbert LLP, London
  • PJ McCarthy, Partner, Goodwin

The Role of Regulation

Life Sciences - Regulation

Chris Campbell, Chief Strategist at Kroll, Michael Kiely, President of U.S. Government Affairs at UPS and John Selib, Senior Vice President, Global Policy & Public Affairs at Pfizer, sat down for a fireside chat on the impact of regulation on the life sciences industry as well as emerging hot topics. 

Key Insights

  • Will regulators be globally aligned?
  • ESG Regulation under the Biden Administration
  • Is there potential for industry and regulators to work closely in sharing ‘real-time’ data
  • Critical emerging trends and hot topics


  • Chris Campbell, Chief Strategist, Kroll
  • John Selib, Senior Vice President, Global Policy & Public Affairs, Pfizers
  • Michael Kiely, President of U.S. Government Affairs, UPS

Navigating the Elevated Risk Environment

Life Sciences - Risk Environment

This discussion provides insights on how the post-COVID-19 environment is challenging for the pharmaceutical and medical device industries. The increased public scrutiny and rapid development of and changes to these industries over the past year amplifies existing operational risks. Our panel of experts addressed evolving risks challenging life sciences global supply chains, including around price gouging rules, how to identify risk exposure and navigate the complex regulatory landscape.

Key Insights

  • Developing strategies that de-risk businesses and operating models
  • Overview of various U.S. and a selection of other government policies and actions impacting the life science’s global supply chains, including for example, price gouging rules
  • Anticipating and addressing increased costs of compliance
  • Strengthening procedures around risk management


  • Roeland Van Aelst, EMEA Lead Third Party Intermediary Ethics & Compliance, Johnson & Johnson
  • John Ingrassia, Senior Counsel, Proskauer Rose LLP
  • Tasneem Azad, Managing Director, Duff & Phelps, a Kroll Business
  • Daniel Hartnett, Associate Managing Director, Kroll


Valuation of businesses, assets and alternative investments for financial reporting, tax and other purposes.

Corporate Finance and Restructuring

Middle Market M&A, Strategic Advisory, Debt Advisory and Private Capital Markets, Restructuring and Insolvency Services, Financial Due Diligence, Fairness Opinions, Solvency Opinions and ESOP/ERISA Advisory.

Compliance Risk and Diligence

Complying with anti-money laundering and anti-bribery and corruption regulations.

Forensic Investigations and Intelligence

Kroll’s forensic investigations and intelligence team delivers actionable data and insights to help clients across the world make critical decisions and mitigate risk.

Transaction Advisory Services

Seamless analytical advisory through the deal continuum, from transaction origination to closing.

Cyber Risk

Incident response, digital forensics, breach notification, managed detection services, penetration testing, cyber assessments and advisory.

Enterprise Security Risk Management

Kroll’s Enterprise Security Risk Management practice provides expert guidance and advisory services to our global clientele as they navigate the most challenging and emerging security and threat-related issues.

Financial Services Compliance and Regulation

End-to-end governance, advisory and monitorship solutions to detect, mitigate, drive efficiencies and remediate operational, legal, compliance and regulatory risk.

Expert Services

Independent expert analysis, testimony, advice and investigations for complex disputes and projects.